Current status of research and application of meningococcal vaccine at home and abroad

Abstract

Abstract: With the use of meningococcal vaccines,the incidence rate of epidemic cerebrospinal meningitis has shown a downward trend. At present,in national immunization program,the vaccination procedures for children are mainly group A meningococcal polysaccharide vaccine and group A and group C meningococcal polysaccharide vaccine. Other meningococcal vaccines on the market in China are mostly group A and group C meningococcal polysaccharide conjugate vaccine and group a,c,y and w meningococcal polysaccharide conjugate vaccine（ACYW）. However,in the United States and some European countries,group ACYW meningococcal polysaccharide conjugate vaccine has been included in immunization programs for a long time. In 2021,the first quadrivalent meningococcal polysaccharide conjugate vaccine in China was launched, making new progress in the research and development of high quality meningococcal vaccines in China. Overall,the development of meningococcal vaccine still has problems such as imperfect immunization procedures and lack of group B meningococcal vaccine. Therefore,this article aims to provide a reference for future development and vaccination of meningococcal vaccines by reviewing the current status and vaccination procedures of meningococcal vaccines both domestically and internationally.

Key words: Meningococcal vaccine, Epidemic cerebrospinal meningitis, Immunization program

CLC Number:

R186

GAO Ping, LIU Hualei, ZANG Zhaohui. Current status of research and application of meningococcal vaccine at home and abroad. [J]OCCUPATION AND HEALTH, 2024, 40(10): 1430-1434.

References

[1] 邵祝军. 中国流行性脑脊髓膜炎流行变异趋势[J].中华预防医学杂志,2013,47(10):891-893.
[2] 刘建舫. 流脑疫苗接种方案对儿童群体接种效果的影响[J].中国处方药,2019,17(7):146-147.
[3] WANG B,SANTORENEOS R,GILES L,et al.Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis[J].Vaccine,2019,37(21):2768-2782.
[4] SCHAFFER DEROO S,TORRES R G,FU L Y.Meningococcal disease and vaccination in college students[J].Hum Vaccin Immunother,2021, 17(11):4675-4688.
[5] 徐颖华,徐苗,叶强.流行性脑脊髓膜炎的流行趋势变化与其疫苗接种[J].实用预防医学,2022,29(8):1015-1019.
[6] 肖耿吉,刘静.认识流行性脑脊髓膜炎[J].家庭医学,2021(11):4-5.
[7] XU J,CHEN Y,YUE M,et al.Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China,2010-2020:a systematic review and meta-analysis[J].Hum Vaccin Immunother,2022,18(5):2071077.
[8] 中国政府网.国家卫生健康委关于印发国家免疫规划疫苗儿童免疫程序及说明(2021年版)的通知[EB/OL].(2022-10-24)[2023-08-04].http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml.
[9] 国家药品监督管理局.我国上市的流脑疫苗[EB/OL].(2022-10-24) [2023-08-04].https://www.nmpa.gov.cn/datasearch/home-index.html#category=yp.
[10] U.S. FOOD & DRUG ADMINISTRATION.Vaccines Licensed for Use in the United States[EB/OL].(2023-7-20)[2023-08-04].https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
[11] EUROPEAN MEDICINES AGENCY[EB/OL].(2022-10-24) [2023-08-04].https://www.ema.europa.eu/en/search/search/field_ema_web_topics%3Aname_field/Vaccines.
[12] POLAND G A.Prevention of meningococcal disease:Current use of polysaccharide and conjugate vaccines[J].Clin Infect Dis,2010,50 Suppl 2:S45-S53.
[13] 赵东阳,谢志强,苟锦博,等.3月龄婴儿接种A群C群脑膜炎球菌多糖结合疫苗的免疫原性和不良反应[J].中国疫苗和免疫,2020, 26(4):387-390.
[14] 范仁锋,汤妍,苏家立,等.A群C群脑膜炎球菌多糖疫苗在广东省2~6岁儿童的免疫原性和免疫持久性研究[J].广东医学,2020,41(12):1241-1244.
[15] 胡家垒,胡月梅,梁祁,等.A群C群脑膜炎球菌结合疫苗安全性和免疫原性[J].中国公共卫生,2020,36(5):765-770.
[16] 画伟. 流脑疫苗接种的注意事项[J].家庭医学,2021(11):9.
[17] AYE A M M,BAI X,BORROW R,et al.Meningococcal disease surveillance in the Asia-Pacific region(2020):The global meningococcal initiative[J].J Infect,2020,81(5):698-711.
[18] SAFADI M A P,GONZALEZ-AYALA S,JAKEL A,et al.The epidemiology of meningococcal disease in Latin America 1945-2010:an unpredictable and changing landscape[J].Epidemiol Infect,2013,141(3):447-458.
[19] 张莉萍,叶雪仪,熊慧璋,等.我国首例感染Y群脑膜炎奈瑟菌CC23病例的实验室分析[J].疾病监测,2020,35(7):664-667.
[20] 黄谷孙,刘美真,柯碧霞,等.汕头市首例ST-1655型Y群流脑的病原学及流行病学分析[J].热带医学杂志,2022,22(5):724-726,731.
[21] 方艳梅,高盛庭,刘美真,等.珠海市首例Y群流行性脑脊髓膜炎病例流行病学和病原学特征[J].中国疫苗和免疫,2021,27(4):398-402.
[22] 贾肇一,王良群,何宝花,等.河北省W群ST-11型脑膜炎奈瑟菌感染死亡病例报告[J].实用预防医学,2021,28(8):1009-1010.
[23] 张学潮,车鑫仁,张小平,等.杭州市一起W135群脑膜炎奈瑟菌感染疫情调查[J].国际流行病学传染病学杂志,2021,48(1):55-58.
[24] 梁海峰,王慧,张萍.2006—2018年山西省流行性脑脊髓膜炎流行病学特征及菌群变迁趋势分析[J].预防医学论坛,2020,26(1):40-42.
[25] FLOUNTZI A,GEORGAKOPOULOU T,BALASEGARAM S,et al.Epidemiology of invasive meningococcal disease in Greece,2006-2016[J].Eur J Clin Microbiol Infect Dis,2019,38(12):2197-2203.
[26] VILLENA R,VALENZUELA M T,BASTIAS M,et al.Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction[J].Vaccine,2022,40(4):666-672.
[27] BLOCK S L,SHEPARD J,GARFIELD H,et al.Immunogenicity and safety of a 3-and 4-dose vaccination series of a meningococcal acwy conjugate vaccine in infants:results of a phase 3b,randomized,open-label trial[J].Pediatr Infect Dis J,2016,35(2):e48-e59.
[28] 谢志强,赵东阳,黄海涛,等.ACYW135群脑膜炎球菌结合疫苗接种于3月龄婴儿的安全性和免疫原性Ⅲ期临床试验研究[J].中华预防医学杂志,2020,54(9):947-952.
[29] VESIKARI T,BORROW R,FORSTEN A,et al.Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine(MenACYW-TT) in healthy toddlers:A Phase II randomized study[J].Hum Vaccin Immunother,2020,16(6):1306-1312.
[30] CHANG L J,HEDRICK J,CHRISTENSEN S,et al.A Phase II,randomized,immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine,MenACYW-TT,in healthy adolescents in the United States[J].Vaccine,2020,38(19):3560-3569.
[31] MEMISH Z A,DBAIBO G,MONTELLANO M,et al.Immunogenicity of a single dose of tetravalent meningococcal serogroups a,c,w-135,and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile[J].Pediatr Infect Dis J,2011,30(4):e56-e62.
[32] 杜风. 小儿接种疫苗需谨慎[J].农家致富,2005,41(5):51.
[33] CHENG W Y,CHANG R,NOVY P,et al.Determinants of Meningococcal ACWY vaccination in adolescents in the US:Completion and compliance with the CDC recommendations[J].Hum Vaccin Immunother,2020, 16(1):176-188.
[34] 王斌冰,毛雷婧,罗献伟,等.2004—2019年安徽省0~2岁儿童流行性脑脊髓膜炎流行病学特征[J].实用医学杂志,2021,37(12):1613-1618.
[35] 陈曦.国内首个自主研发四价流脑疫苗正式获批[N].科技日报,2021-12-30(002).
[36] 谢志强,黄海涛,张伟,等.一种国产ACYW135群脑膜炎球菌多糖结合疫苗在3月龄、6-23月龄和2-6岁儿童中安全性的Ⅲ期临床试验[J].中国疫苗和免疫,2021,27(6):648-654.
[37] 谢志强,苟锦博,张伟,等.一种国产ACYW135群脑膜炎球菌多糖结合疫苗在3月龄、6-23月龄和2-6岁儿童中的免疫原性[J].中国疫苗和免疫,2021,27(5):540-546.
[38] PARIKH S R,CAMPBELL H,BETTINGER J,et al.The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination[J].J Infect,2020,81(4):483-498.
[39] 徐颖华,李亚南,叶强.中国脑膜炎球菌疫苗发展现状与挑战[J].中国公共卫生,2022,38(7):948-951.
[40] MARTINS R M,PERISSE A R S,CAMACHO L A B,et al.Phase I safety and immunogenicity study of a Brazilian serogroup B vaccine[J].Braz J Infect Dis.2021,25(6):101652.
[41] CHIU N C,HUANG L M,WILLEMSEN A,et al.Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan:A phase 3,open-label,randomized study[J].Hum Vaccin Immunother.2018,14(5):1075-1083.
[42] BLOCK S L,SZENBORN L,DALY W,et al.A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized,controlled trial[J].Vaccine,2015, 33(21):2500-2510.
[43] 中华预防医学会.中国脑膜炎球菌疫苗预防接种专家共识(2023 年版)[J].中国预防医学杂志,2023,24(2):81-92.